Johnson & Johnson (NYSE: JNJ) definitive agreement to acquire Omrix Biopharmaceuticals, Inc. (Nasdaq: OMRI) for approximately $438 million in a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE